Edwards Lifesciences Corporation $EW Stock Sold by Ninety One UK Ltd

Key Points

• Ninety One UK Ltd reduced its Edwards Lifesciences stake by 3.2%, selling 393,827 shares and retaining 11.94 million shares valued at approximately $1.03 billion. Institutional investors collectively own 79.46% of the company.
• Wall Street sentiment remains positive, with analysts assigning a consensus “Moderate Buy” rating and an average price target of $100.27, above the stock’s reported price of $86.53.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in earnings per share versus a $0.74 estimate and $1.74 billion in revenue, up 13.6% year over year. Company insiders, however, sold 5,045 shares worth $451,596 during the last quarter.

Ninety One UK Ltd lessened its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 3.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,943,675 shares of the medical research company's stock after selling 393,827 shares during the quarter. Edwards Lifesciences makes up 2.4% of Ninety One UK Ltd's investment portfolio, making the stock its 8th largest holding. Ninety One UK Ltd owned approximately 2.07% of Edwards Lifesciences worth $1,030,978,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Rehmann Capital Advisory Group grew its holdings in Edwards Lifesciences by 2.1% in the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock worth $546,000 after acquiring an additional 130 shares during the last quarter. NorthRock Partners LLC raised its stake in shares of Edwards Lifesciences by 1.0% during the second quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company's stock valued at $1,465,000 after acquiring an additional 153 shares during the last quarter. Elevation Wealth Partners LLC raised its stake in shares of Edwards Lifesciences by 24.8% during the third quarter. Elevation Wealth Partners LLC now owns 779 shares of the medical research company's stock valued at $67,000 after acquiring an additional 155 shares during the last quarter. Plan A Wealth LLC boosted its holdings in shares of Edwards Lifesciences by 3.0% during the third quarter. Plan A Wealth LLC now owns 5,460 shares of the medical research company's stock worth $471,000 after purchasing an additional 158 shares during the period. Finally, Premier Path Wealth Partners LLC boosted its holdings in shares of Edwards Lifesciences by 4.4% during the first quarter. Premier Path Wealth Partners LLC now owns 3,880 shares of the medical research company's stock worth $311,000 after purchasing an additional 162 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on EW. Mizuho increased their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 15th. Barclays raised Edwards Lifesciences to a "strong-buy" rating in a research report on Wednesday, October 7th. Truist Financial raised their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company a "hold" rating in a research note on Thursday, July 16th. BTIG Research restated a "buy" rating and set a $110.00 price target on shares of Edwards Lifesciences in a research report on Friday, September 11th. Finally, UBS Group restated a "buy" rating on shares of Edwards Lifesciences in a research report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus target price of $100.27.

Insider Buying and Selling at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 544 shares of the business's stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president directly owned 14,868 shares of the company's stock, valued at approximately $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Daniel Lippis sold 619 shares of the firm's stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $85.65, for a total value of $53,017.35. Following the transaction, the vice president owned 40,034 shares in the company, valued at $3,428,912.10. This represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,045 shares of company stock valued at $451,596 over the last quarter. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Trading Up 0.1%

Edwards Lifesciences stock traded up $0.08 during midday trading on Thursday, reaching $86.53. The stock had a trading volume of 1,294,080 shares, compared to its average volume of 4,491,407. The firm has a market cap of $49.82 billion, a price-to-earnings ratio of 49.80, a price-to-earnings-growth ratio of 2.23 and a beta of 0.87. The company has a fifty day moving average of $88.53 and a 200 day moving average of $86.27. Edwards Lifesciences Corporation has a 52-week low of $72.42 and a 52-week high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm's revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 3.00 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.